Menarini extends rights to Teijin's gout drug febuxostat
This article was originally published in Scrip
Executive Summary
Menarini has extended its commercial alliance for Teijin Pharma's gout drug febuxostat to a further 26 mainly emerging markets, acquiring exclusive distribution and marketing rights in Central and South America, the Commonwealth of Independent States and Australia/New Zealand.